title: Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.
abstract: Risk of cardiotoxicity is the most serious drawback of the clinical usefulness of anthracycline antineoplastic antibiotics, which however, remain among the most powerful and widely employed anticancer drugs. In this study we have used daunorubicin-induced cardiomyopathy in rabbits as a model to investigate possible cardioprotective effects of pyridoxal isonicotinoyl hydrazone (PIH)-a principal representative of a novel group of aroylhydrazone iron chelators. Three groups of animals were used: a control group (n=11; i.v. saline), daunorubicin-treated animals (n=11; 3mg/kg, i.v.), and animals pretreated with PIH (n=9, 25 mg/kg, i.p.) 60 min before daunorubicin administration. All substances were administered once weekly for 10 weeks. Repeated administration of daunorubicin caused premature death in four animals and induced conspicuous histopathological changes in the myocardium, progressive and significant impairment of systolic heart function (a decrease in left ventricular dP/dt(max), ejection fraction, an increase in the pre-ejection period/left ventricular ejection time index), and a gradual increase in cardiac troponin T plasma concentrations. On the contrary, all the PIH-treated animals have survived all daunorubicin applications. Furthermore, in this group, the daunorubicin-induced cardiac changes were in most functional, biochemical as well as morphological parameters less pronounced than in the group receiving daunorubicin alone. Hence, PIH and other aroylhydrazones merit further investigation as potentially protective agents against anthracycline-induced cardiotoxicity.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. simunekt@faf.cuni.cz
authors.forename: T
authors.initials: T
authors.lastname: Simůnek
authors.forename: I
authors.initials: I
authors.lastname: Klimtová
authors.forename: J
authors.initials: J
authors.lastname: Kaplanová
authors.forename: M
authors.initials: M
authors.lastname: Sterba
authors.forename: Y
authors.initials: Y
authors.lastname: Mazurová
authors.forename: M
authors.initials: M
authors.lastname: Adamcová
authors.forename: R
authors.initials: R
authors.lastname: Hrdina
authors.forename: V
authors.initials: V
authors.lastname: Gersl
authors.forename: P
authors.initials: P
authors.lastname: Ponka
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology*; D003630:Daunorubicin / Q000633:toxicity*; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007538:Isoniazid / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008297:Male; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D011730:Pyridoxal / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011817:Rabbits
chemical_list: D002316:Cardiotonic Agents; D011730:Pyridoxal; C021079:pyridoxal isonicotinoyl hydrazone; D007538:Isoniazid; D003630:Daunorubicin